Thermo Fisher Scientific Inc (TMO) concluded trading on Thursday at a closing price of $427.44, with 3.84 million shares of worth about $1.64 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.22% during that period and on April 10, 2025 the price saw a loss of about -5.76%. Currently the company’s common shares owned by public are about 380.77M shares, out of which, 376.61M shares are available for trading.
Stock saw a price change of -9.06% in past 5 days and over the past one month there was a price change of -16.62%. Year-to-date (YTD), TMO shares are showing a performance of -17.84% which decreased to -27.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $409.85 but also hit the highest price of $627.88 during that period. The average intraday trading volume for Thermo Fisher Scientific Inc shares is 2.10 million. The stock is currently trading -12.71% below its 20-day simple moving average (SMA20), while that difference is down -18.02% for SMA50 and it goes to -23.26% lower than SMA200.
Thermo Fisher Scientific Inc (NYSE: TMO) currently have 380.77M outstanding shares and institutions hold larger chunk of about 91.55% of that.
The stock has a current market capitalization of $161.26B and its 3Y-monthly beta is at 0.83. PE ratio of stock for trailing 12 months is 25.87, while it has posted earnings per share of $16.52 in the same period. Its PEG reads 2.64 and has Quick Ratio of 1.29 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TMO, volatility over the week remained 9.06% while standing at 3.87% over the month.
Stock’s fiscal year EPS is expected to rise by 6.47% while it is estimated to increase by 10.49% in next year. EPS is likely to shrink at an annualized rate of 9.79% for next 5-years, compared to annual growth of 12.52% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Bernstein on January 10, 2025 offering an Outperform rating for the stock and assigned a target price of $630 to it. On October 14, 2024, Redburn Atlantic Initiated their recommendations, while on October 01, 2024, Stephens Initiated their ratings for the stock with a price target of $680. Stock get an Overweight rating from Wells Fargo on August 28, 2024.
